Search

Your search keyword '"Jacob Haaber"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Jacob Haaber" Remove constraint Author: "Jacob Haaber" Topic medicine.disease Remove constraint Topic: medicine.disease
42 results on '"Jacob Haaber"'

Search Results

1. Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4

2. Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Catalog

Books, media, physical & digital resources

3. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

4. Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma

5. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

6. Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

7. Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

8. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

9. Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

10. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy:an international study of 264 real-world patients

11. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

12. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19

13. Early progression of mantle cell lymphoma depicts a high-risk disease with poor response to subsequent therapies and a dismal outcome

14. Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma

15. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma

16. Erratum to 'Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma' [Experimental Hematology 84 (2020) 7–18]

17. B-CAP (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and predniso(lo)Ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase II intergroup trial By the German Hodgkin study group (GHSG) and the Nordic Lymphoma group (NLG)

18. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

19. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines

20. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma:a Nordic Lymphoma Group population-based study

21. An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

22. Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

24. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease

25. Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

26. Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

27. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

28. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

29. The Danish National Lymphoma Registry: Coverage and Data Quality

30. Danish National Lymphoma Registry

31. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer–host partnership?

32. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis

33. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration

34. Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis

35. Characterization of potential CD138 negative myeloma 'stem cells'

36. Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

37. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders

38. Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

39. Bone Marrow Microenvironmental Overexpression of DKK1, HGF, Frizzled-Related Protein B, and Syndecan-1 Are Associated with the Degree of Osteolytic Bone Disease in Multiple Myeloma Patients

40. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

41. Myeloma Cell Expression of Candidate Genes for Osteolytic Bone Disease - Over-Expression of DKK1 Correlates with Clinical Bone Involvment

42. Interphase FISH in Multiple Myeloma